IGC Pharma Inc (IGC)
0.508
+0.03
(+6.70%)
USD |
NYAM |
Apr 19, 15:27
IGC Pharma Revenue (TTM): 1.216M for Dec. 31, 2023
Revenue (TTM) Chart
Historical Revenue (TTM) Data
| Date | Value |
|---|---|
| December 31, 2023 | 1.216M |
| September 30, 2023 | 1.344M |
| June 30, 2023 | 1.255M |
| March 31, 2023 | 0.912M |
| December 31, 2022 | 0.868M |
| September 30, 2022 | 0.678M |
| June 30, 2022 | 0.532M |
| March 31, 2022 | 0.397M |
| December 31, 2021 | 0.356M |
| September 30, 2021 | 0.322M |
| June 30, 2021 | 0.391M |
| March 31, 2021 | 0.898M |
| December 31, 2020 | 0.846M |
| September 30, 2020 | 1.311M |
| June 30, 2020 | 3.007M |
| March 31, 2020 | 4.072M |
| December 31, 2019 | 5.585M |
| September 30, 2019 | 6.297M |
| June 30, 2019 | 5.287M |
| March 31, 2019 | 5.116M |
| December 31, 2018 | 4.716M |
| September 30, 2018 | 4.193M |
| June 30, 2018 | 3.617M |
| March 31, 2018 | 2.192M |
| December 31, 2017 | 1.143M |
| Date | Value |
|---|---|
| September 30, 2017 | 0.6307M |
| June 30, 2017 | 0.5579M |
| March 31, 2017 | 0.7935M |
| December 31, 2016 | 2.068M |
| September 30, 2016 | 2.903M |
| June 30, 2016 | 4.797M |
| March 31, 2016 | 6.367M |
| December 31, 2015 | 7.256M |
| September 30, 2015 | 8.713M |
| June 30, 2015 | 8.775M |
| March 31, 2015 | 7.680M |
| December 31, 2014 | 5.422M |
| September 30, 2014 | 2.897M |
| June 30, 2014 | 1.913M |
| March 31, 2014 | 2.273M |
| December 31, 2013 | 3.752M |
| September 30, 2013 | 7.668M |
| June 30, 2013 | 7.886M |
| March 31, 2013 | 8.03M |
| December 31, 2012 | 7.793M |
| September 30, 2012 | 4.846M |
| June 30, 2012 | 4.407M |
| March 31, 2012 | 4.200M |
| December 31, 2011 | 3.739M |
| September 30, 2011 | 3.236M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (TTM) Range, Past 5 Years
0.322M
Minimum
Sep 2021
6.297M
Maximum
Sep 2019
1.872M
Average
0.912M
Median
Mar 2023
Revenue (TTM) Benchmarks
| CEL-SCI Corp | -- |
| AIM ImmunoTech Inc | 0.202M |
| NovaBay Pharmaceuticals Inc | 14.73M |
| Protalix BioTherapeutics Inc | 65.49M |
| Palatin Technologies Inc | 7.098M |